GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SpA (MEX:STVN N) » Definitions » 3-Month Share Buyback Ratio

Stevanato Group SpA (MEX:STVN N) 3-Month Share Buyback Ratio : 0.00% (As of Mar. 2025 )


View and export this data going back to 2022. Start your Free Trial

What is Stevanato Group SpA 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Stevanato Group SpA's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Stevanato Group SpA's 3-Month Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stevanato Group SpA's 3-Month Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Stevanato Group SpA's 3-Month Share Buyback Ratio falls into.


;
;

Stevanato Group SpA 3-Month Share Buyback Ratio Calculation

Stevanato Group SpA's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2024 ) - Shares Outstanding (EOP) (Mar. 2025 )) / Shares Outstanding (EOP) (Dec. 2024 )
=(272.899 - 272.899) / 272.899
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stevanato Group SpA  (MEX:STVN N) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Stevanato Group SpA 3-Month Share Buyback Ratio Related Terms

Stevanato Group SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SpA (MEX:STVN N) » Definitions » 3-Month Share Buyback Ratio
Comparable Companies
RGEN MMSI TFX AVTR NVST ICUI XRAY ATR WRBY LMAT ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 XPAR:DIM OCSE:COLO B XSWX:STMN
Traded in Other Exchanges
STVN:USA 87N:Germany
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Website
https://www.stevanatogroup.com
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Stevanato Group SpA Headlines

No Headlines